Safi Biotherapeutics

Executive Summary

Safi Biotherapeutics is a pre-clinical biotechnology company developing manufactured red blood cells (mRBCs) from adult stem cells. The company aims to address the critical need for a safe, reliable, and scalable blood supply for civilian and military transfusions, reducing dependence on donors and mitigating supply shortages. Founded in 2020 and headquartered in San Diego, Safi is advancing its platform through GMP manufacturing and targets initiating clinical trials in 2027. The technology has potential applications in trauma care, surgery, and chronic anemias, positioning the company as a key player in regenerative medicine and transfusion biology. Safi’s progress to date includes establishing a robust manufacturing process for mRBCs, with a focus on cost-efficiency and compatibility. The company is actively engaging with regulatory bodies and potential partners in the military and healthcare sectors. Key upcoming milestones include scaling up GMP production, completing IND-enabling studies, and filing an IND application. While still in early stages, Safi’s differentiated approach and clear market need support a promising outlook, contingent on successful technical and regulatory execution.

Upcoming Catalysts (preview)

• Q3 2026GMP Manufacturing Scale-Up Completion80% success
• 2027IND Filing for First Clinical Trial60% success
• Q4 2026Strategic Partnership with Military or Blood Bank Organization50% success